[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[3] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[4] |
WANG Yi, REN Jingtian.
Evaluation and significance of benefit-risk analysis of benzbromarone-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 189-192.
|
[5] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
[6] |
YU Hongli, PANG Yu, SHAO Bo, XIAO Aili, YU Dongmei.
Current Adverse Drug Reaction Reporting and Monitoring of Essential Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768.
|
[7] |
ZHENG Mingjie, ChENG Rong, SONG Haibo.
Bibliometric Analysis of Pharmacovigilance Research in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 686-688.
|
[8] |
FAN Yan, WANG Dan, WANG Chunting.
The Mechanism of Toxicity Reaction Induced by Protamine Sulfate Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1159-1161.
|
[9] |
XUE Wei, QI Wenyuan, LIU Yue, CONG Duanduan, LIU Xiaohui, LI Hongyan, WANG Juan, LI Kexin, HU Xin.
Design and Implementation of Bioequivalence Tests Based on Risk Management Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 549-552.
|
[10] |
YANG Yue.
Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.
|
[11] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.
|
[12] |
ZHANG Rui, PAN Yan, WU Zhiang.
Quality Risk Management during Implementation of Phase Ⅱa Clinical Trials of Innovative Anti-tumor Drugs
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 886-889.
|
[13] |
ZOU Limin, QI Yueli, TANG Ling, DU Yu, YANG Zhimin.
How to Develop a Post-marketing Risk Management Plan for New Drug Applications in Line with E2E Guidelines
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 780-784.
|
[14] |
SANG Yuan, WU Shifu, LU Changfei, XIE Yanjun, CUI Xiaokang, XU Lili, LIU Wenwen, HUO Yanfei.
Problems and Thoughts on Reporting and Monitoring of Adverse Drug Reactions in Drug Manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.
|
[15] |
WANG Dan, LI Xinling, DONG Duo, XIONG Weiyi, LIU Cuili, ZHU Lan, GENG Fengying, LIAO Jianbo, YANG Yueming, LAN Shan, LV Xiaoqin, WANG Tongchun, ZHAO Xia, WANG Wen.
Investigation of Pharmaceutical Manufacturers’ Ability of Direct Reporting of Drug Adverse Reactions
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 654-661.
|